Improving Outcomes for Patients Through the Optimal Integration of HER2-Targeted Antibody–Drug Conjugate Therapy

Explore expert insights on the optimal utilization of HER2-targeted ADCs in patients with advanced NSCLC in an on-demand webcast derived from a live event. Then, download the accompanying slides for a comprehensive reference on the latest advancements in treatment strategies.

Share

Program Content

Activities

HER2-Targeted Therapy in NSCLC
Improving Outcomes for Patients With Advanced NSCLC Through the Optimal Integration of HER2-Targeted Antibody–Drug Conjugate Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 25, 2023

Activities

HER2-Targeted Therapy for NSCLC
Improving Outcomes for Patients With Advanced NSCLC Through the Optimal Integration of HER2-Targeted Antibody–Drug Conjugate Therapy
Video
Congratulations: You achieved a completion on 04/09/2022

Released: December 01, 2023

Expires: November 30, 2024

Faculty

cover img faculity

Lyudmila Bazhenova, MD

Lung Cancer Unit Leader
Director 
Hematology and Oncology Training Program
University of California 
San Diego, California

cover img faculity

Nisha Mohindra, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Feinberg School of Medicine of Northwestern University
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

cover img faculity

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Professor, Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.